Trials / No Longer Available
No Longer AvailableNCT04302766
Expanded Access Remdesivir (RDV; GS-5734™)
Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Detailed description
The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV; GS-5734™) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remdesivir | Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp). |
Timeline
- First posted
- 2020-03-10
- Last updated
- 2022-02-17
Locations
22 sites across 8 countries: United States, Afghanistan, Djibouti, Germany, Guam, Iraq, Japan, Kuwait
Source: ClinicalTrials.gov record NCT04302766. Inclusion in this directory is not an endorsement.